News

Press Releases

Filter By

2022/11/30

WuXi AppTec Receives 2022 Global Contract Research, Development and Manufacturing Organization Company of the Year Award from Frost & Sullivan

SHANGHAI, November 29, 2022 – WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services for the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, announced that it is a recipient of the 2022 Global Contract Research, Development and Manufacturing Organization Company of the Year Award from Frost & Sullivan, a global research & consulting firm that helps customers accelerate growth. This marks the sixth consecutive year that WuXi AppTec has been recognized by Frost & Sullivan for its leadership and innovative services.

Read more

2022/10/26

WuXi AppTec Reports Record Year-to-Date Results in 2022, Third Quarter Revenue over RMB10 Billion

(SHANGHAI, October 26, 2022) — WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its financial results for the third quarter and nine months ended September 30, 2022 (“Reporting Period”).

Read more

2022/09/26

WuXi STA Opens First High Potency Oral Drug Product Manufacturing Facility

New facility expands integrated drug product R&D and manufacturing services to global customers

Read more

2022/09/09

WuXi STA Opens a New Sterile Lipid Nanoparticle Formulation Facility to Enhance Global CRDMO Services for Customers

SHANGHAI, September 9, 2022 – WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its Wuxi city campus. Created in response to the increasing demand for complex injection dosage forms, this new facility marks the company’s fast-growing parenteral formulation capabilities and is yet another opportunity to enable customers as they develop and deliver better medicines for patients.

Read more

2022/08/17

WuXi STA Breaks Ground for New Pharmaceutical Manufacturing Facility in Middletown, Delaware

MIDDLETOWN, Delaware, August 16, 2022 – WuXi STA, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the groundbreaking for its new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware. First announced in June 2021, this site will be WuXi STA’s second facility in the United States, offering expanded capacity and greater flexibility to meet the needs of customers in the U.S. and around the world.

Read more